Timothy Chiang Recent News
Synergy's Incoming FDA Catalyst
Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision
Valeant Shares Surge, But BTIG Remains Cautious On Recovery
BTIG Still Buying Relypsa As May Prescription Trends Show Steady Veltassa Increases
As Veltassa Continues To Grow, BTIG Still Buying Relypsa
BTIG Cuts Veltassa Estimates, Relypsa's Price Target To $35
Perrigo's CEO Departure Leaves More Questions Than Answers; BTIG Downgrades Stock
Shire Just Took Another Step Forward With Its ADHD Drug
BTIG: Buy Teva On Weakness, U.S. Lawmakers Have Little Appetite For Direct Government Negotiation Of Drug Prices
BTIG Recommends 'Beaten Down' Drug Manufacturers Like Teva